ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ICLR / options
CRL (64) MEDP (77) INCY (88) IQV (61) ⌘ Pro Terminal →

ICON plc (ICLR) Options Positioning, Max Pain & Unusual Sweeps

$205.14 -2.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $204.55

ICON plc (ICLR) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (steady margins, 3% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $16.18B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ICLR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ICLR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ICON plc (NASDAQ: ICLR) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $205.14 (-2.94% 1D, market cap $16.18B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, ICLR ranks #56 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ICLR compare to CRL and MEDP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ICLR carries a Roarable B (72/100 RQD), trailing P/E of 71.9x, gross margin of —, and ROIC of 3.1%. By comparison, CRL (Charles River Laboratories International Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 0.4%, cap $17.16B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ICLR?
▼

Per ICLR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001060955), ICON plc generated $8.25B in revenue (+0.8% YoY), $229.3M in net income, and $862.0M in free cash flow against $16.27B in total assets and $2.87B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 72x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $204.55 (-0.29%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 10.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B- · Rk B
Cash (12)Whales (19)SEC (14)Macro (16)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$257 Bull$218 Base$168 Bear
📬 FREE ICLR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICLR)Realized 20D OHLCV Swing Band: ±9.3%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY ICLR SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (26% of score)

20D Institutional Volume Accumulation (±9.3% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (22% of score)

FRED Regime × Technicals: 91% of 52W Range • RSI-14 at 70.6 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$168.97+9.6% Next Q
Q2 (-2Q)
67
Grade B-$185.25+15.6% Next Q
Q3 (-1Q)
69
Grade B-$214.16-4.2% Next Q
Current
72
Grade B$205.14+7% Hist 90D α
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ICLR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, ICLR faces multiple-compression risk if 71.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 72x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($174.52) or 200D SMA ($146.31) invalidates the momentum regime and cuts Target Base ($218.06) toward Bear Floor ($168.21).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICLR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ICLR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±9.3%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ICLR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ICLR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating ICLR & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on ICLR
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ICLR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +83.21%▲ ASCENDING CHANNEL
2026-11-03O $215.5H $215.5L $205.1C $205.1VOL 2.58M
RES: $222.2SUP: $160.3SMA50: $174.5SMA200: $146.3
$226.9$194.4$162.0$129.6$97.16RES $222.2SUP $160.3$205.12026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICLR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICLR Butterfly Map → + Track ICLR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
46.6%/yr Implied 5Y Growth

vs. +0.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ICLR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICLR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ICLR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICLR)

Health Care Rank #56 of 1015 ⚔️ CRL vs ICLR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICLR vs. CRL, MEDP, INCY, IQV)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ICON plc (ICLR) ranks #56 by composite RQD confidence (72/100, grade B) and #77 by equity capitalization ($16.18B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 88/100 (A) compared with ICLR at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ICLR ACTIVE
ICON plc
B 72/100 71.9x — 3.1% -2.94% $16.18B Benchmark Subject
CRL
Charles River Laboratories International Inc.
C 64/100 — — 0.4% -5.81% $17.16B /crl-vs-iclr →
MEDP
Medpace Holdings Inc.
B+ 77/100 42.0x — 27.9% -0.59% $18.24B /medp-vs-iclr →
INCY
Incyte Corp.
A 88/100 18.4x 92.8% 42.4% -0.29% $24.54B /incy-vs-iclr →
IQV
IQVIA Holdings Inc.
C- 61/100 33.3x — 9.4% -3.32% $44.06B /iqv-vs-iclr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001060955 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ICON plc (ICLR) reported GAAP revenue of $8.25B (+0.8% vs. FY2024 revenue of $8.19B , and +2.4% cumulative change since FY2023) , GAAP net income of $229.3M, operating cash flow of $1.04B, and free cash flow of $862.0M (-22.9% YoY). On the balance sheet, ICLR closed FY2025 with $16.27B in total assets against $2.87B in total debt (Altman Z-Score: 2.20, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $8.25B $229.3M $1.04B $862.0M $16.27B $2.87B
FY2024 (FY) 2024-12-31 $8.19B $739.1M $1.29B $1.12B $16.63B $3.40B
FY2023 (FY) 2023-12-31 $8.05B $554.2M $1.16B $798.6M $9.67B $2.26B

3. ICLR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICLR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ICON plc (NASDAQ: ICLR) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $205.14 (-2.94% 1D, market cap $16.18B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, ICLR ranks #56 in composite RQD confidence.

How does ICLR compare to CRL and MEDP in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ICLR carries a Roarable B (72/100 RQD), trailing P/E of 71.9x, gross margin of —, and ROIC of 3.1%. By comparison, CRL (Charles River Laboratories International Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 0.4%, cap $17.16B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ICLR?

Per ICLR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001060955), ICON plc generated $8.25B in revenue (+0.8% YoY), $229.3M in net income, and $862.0M in free cash flow against $16.27B in total assets and $2.87B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 72x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ICLR trading relative to its 50-day, 200-day, and 52-week technical levels?

ICLR last traded at $205.14 (-2.94% on volume of 778,595 shares), positioning the stock +17.55% above its 50-day simple moving average ($174.52) and +40.21% above its 200-day simple moving average ($146.31). Across its 52-week range of $66.57 to $219.04, ICLR sits at the 90.9% percentile with a 14-day RSI of 70.6 (OVERBOUGHT (>70)) and an implied next-earnings move of ±9.3% ($186.06 to $224.22).

Direct Sub-Reports: ICLR RQD Cockpit ICLR 12M Forecast ICLR Earnings & Move ICLR Dividends & DRIP ICLR Insiders & 13F ICLR Whale Options ICLR Profit Sankey ICLR News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ SEC XBRL & RQD VERIFIED

ICLR — ICON plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ICON plc (ICLR) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $205.14 (-2.94% 1D, market capitalization $16.18B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 3.1%, gross margin of —, operating margin of 5.4%, and free cash flow yield of 5.22%.
  • Whale 13F & Options Flow (19/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (16/20) + Forensic Balance Sheet (14/20): Incorporates a 1.08x equity beta, Altman Z-Score of 2.20, Piotroski F-Score of 7/9, and Debt/Equity of 0.31x.

2. Business Model, Unit Margins & SEC Financial Trajectory

ICON plc (ICLR) is a NASDAQ-listed issuer in the Health Care sector, classified under the Biotechnology: Commercial Physical & Biological Resarch industry. Its market capitalization is $16.5B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ICON plc (ICLR) reported $8.25B in annual revenue (up from $8.19B in FY2024, +0.8% YoY) and $229.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.05B revenue, $554.2M net income) through FY2025, ICLR scaled operating cash flow to $1.04B and free cash flow to $862.0M, backed by $16.27B in total assets against $2.87B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 72/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 5.22% and institutional whale pillar of 19/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $66.57 – $219.04 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 72x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 71.9x trailing P/E and 31.7x EV/EBITDA against 5.4% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations: — Second-order bottlenecks: — The only sector-level input is the Macro Regime Fit pillar (Beta 1.08; sector sensitivity), which indicates modestly above-market price sensitivity.

  • Key Question #1: Can ICLR sustain or expand its 5.4% operating margin and 3.1% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $8.25B and free cash flow of $862.0M, how will capital allocation balance growth reinvestment against $2.87B in total debt?
  • Key Question #3: How sensitive is ICLR's 66.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

ICLR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ICON plc (ICLR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ICLR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ICLR Bull vs. Bear Conversation Board — What's Your Call at $205.14?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ICLR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ICLR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $274.77 (+30.0%)
📌 Pinned Debate

Institutional whale 13F flow scores 18/20 within the RQD rating, the strongest pillar, indicating sustained accumulation.

Here is why I am bullish on ICLR here at $211.36: Institutional whale 13F flow scores 18/20 within the RQD rating, the strongest pillar, indicating sustained accumulation.. Compare ICLR's 5.4% operating margin and 3.1% ROIC against the rest of Biotechnology: Commercial Physical & Biological Resarch. As long as cash conversion holds up, dips toward $200.79 are getting bought.

CapAlloc_Nerd 🐂 BULL

@MeanReversion_88 Fair point on 71.9x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Commercial Physical & Biological Resarch. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $162.75 (-23.0%)
Spot @ $211.36

A 71.9 trailing P/E against 3.1% ROIC and net income falling from $739.1M to $229.3M leaves valuation dependent on earnings recovery.

Careful chasing ICLR at $211.36. A 71.9 trailing P/E against 3.1% ROIC and net income falling from $739.1M to $229.3M leaves valuation dependent on earnings recovery.. Gross margin is 0.0%, but operating margin is 5.4%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $162.75 on multiple compression.

LIVE TAPE